IL259093A - Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneity - Google Patents
Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneityInfo
- Publication number
- IL259093A IL259093A IL259093A IL25909318A IL259093A IL 259093 A IL259093 A IL 259093A IL 259093 A IL259093 A IL 259093A IL 25909318 A IL25909318 A IL 25909318A IL 259093 A IL259093 A IL 259093A
- Authority
- IL
- Israel
- Prior art keywords
- disease
- ctcs
- blood
- cancer cells
- heterogeneity
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6841—In situ hybridisation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70589—CD45
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562250422P | 2015-11-03 | 2015-11-03 | |
| PCT/US2016/059877 WO2017079139A1 (en) | 2015-11-03 | 2016-11-01 | Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL259093A true IL259093A (en) | 2018-06-28 |
Family
ID=58662599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL259093A IL259093A (en) | 2015-11-03 | 2018-05-02 | Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneity |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20180321247A1 (enExample) |
| EP (1) | EP3371327B1 (enExample) |
| JP (1) | JP7043412B2 (enExample) |
| CN (2) | CN115341033A (enExample) |
| AU (2) | AU2016348401A1 (enExample) |
| CA (1) | CA3004150A1 (enExample) |
| EA (1) | EA201891085A1 (enExample) |
| IL (1) | IL259093A (enExample) |
| WO (1) | WO2017079139A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2491395B1 (en) | 2009-10-21 | 2015-09-16 | The Scripps Research Institute | Method of using non-rare cells to detect rare cells |
| WO2015112955A1 (en) | 2014-01-27 | 2015-07-30 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for prostate cancer biomarkers |
| EA201691682A1 (ru) | 2014-02-21 | 2017-02-28 | Эпик Сайенсиз, Инк. | Способы анализирования редких циркулирующих в крови клеток |
| JP7633173B2 (ja) * | 2019-03-28 | 2025-02-19 | ランドチ ダイアグノスティクス アーベー | ２型糖尿病リスク予測におけるフォリスタチンの使用 |
| US12412272B2 (en) | 2019-11-26 | 2025-09-09 | University Of Cincinnati | Characterizing intra-site tumor heterogeneity |
| CN117497044A (zh) * | 2022-03-09 | 2024-02-02 | 复旦大学 | 基于单细胞基因组拷贝数变异谱在制造细胞良恶性诊断试剂或检测试剂中的应用 |
| WO2024192141A1 (en) | 2023-03-13 | 2024-09-19 | Dana-Farber Cancer Institute, Inc. | Treatment of cancers having a drug-resistant mesenchymal cell state |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014047285A1 (en) * | 2012-09-19 | 2014-03-27 | Paraskevi Giannakakou | Identifying taxane sensitivity in prostate cancer patients |
| DK2981624T3 (da) | 2013-04-05 | 2020-03-02 | Myriad Genetics Inc | Fremgangsmåder til vurdering af homolog rekombinationsdeficiens og forudsigelse af respons på cancerbehandling |
| CN106062561B (zh) | 2013-09-30 | 2021-11-09 | 斯克利普斯研究院 | 为了监测前列腺癌患者中的肿瘤进化进行循环肿瘤细胞的基因型和表型分析 |
| US20150147339A1 (en) * | 2013-11-15 | 2015-05-28 | Psma Development Company, Llc | Biomarkers for psma targeted therapy for prostate cancer |
| US10745760B2 (en) * | 2014-01-17 | 2020-08-18 | University Health Network | Biopsy-driven genomic signature for prostate cancer prognosis |
| WO2015112955A1 (en) * | 2014-01-27 | 2015-07-30 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for prostate cancer biomarkers |
| EP3100052B1 (en) * | 2014-01-30 | 2021-03-10 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for biomarkers predictive of resistance to androgen receptor (ar) targeted therapies |
-
2016
- 2016-11-01 WO PCT/US2016/059877 patent/WO2017079139A1/en not_active Ceased
- 2016-11-01 CN CN202210906018.2A patent/CN115341033A/zh active Pending
- 2016-11-01 US US15/773,154 patent/US20180321247A1/en not_active Abandoned
- 2016-11-01 AU AU2016348401A patent/AU2016348401A1/en not_active Abandoned
- 2016-11-01 CN CN201680078293.2A patent/CN108603233A/zh active Pending
- 2016-11-01 EP EP16862785.9A patent/EP3371327B1/en active Active
- 2016-11-01 EA EA201891085A patent/EA201891085A1/ru unknown
- 2016-11-01 JP JP2018543010A patent/JP7043412B2/ja active Active
- 2016-11-01 CA CA3004150A patent/CA3004150A1/en active Pending
-
2018
- 2018-05-02 IL IL259093A patent/IL259093A/en unknown
-
2021
- 2021-01-06 US US17/142,767 patent/US20210405055A1/en not_active Abandoned
-
2023
- 2023-01-24 AU AU2023200364A patent/AU2023200364A1/en not_active Abandoned
-
2024
- 2024-07-11 US US18/770,366 patent/US20250180564A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018534595A (ja) | 2018-11-22 |
| CN115341033A (zh) | 2022-11-15 |
| US20250180564A1 (en) | 2025-06-05 |
| JP7043412B2 (ja) | 2022-03-29 |
| AU2016348401A1 (en) | 2018-05-24 |
| EP3371327A4 (en) | 2019-07-03 |
| EA201891085A1 (ru) | 2018-11-30 |
| US20210405055A1 (en) | 2021-12-30 |
| US20180321247A1 (en) | 2018-11-08 |
| WO2017079139A1 (en) | 2017-05-11 |
| EP3371327B1 (en) | 2024-12-18 |
| AU2023200364A1 (en) | 2023-02-23 |
| CA3004150A1 (en) | 2017-05-11 |
| EP3371327A1 (en) | 2018-09-12 |
| CN108603233A (zh) | 2018-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL292504B1 (en) | -methods of preparing t cells for t cell therapy | |
| IL288241A (en) | Improved methods of cell culture for adoptive cell therapy | |
| IL290744A (en) | Methods for the production of autologous t cells used in the treatment of b-cell malignancies and other types of cancer and preparations thereof | |
| EP3307876A4 (en) | MODIFIED NK-92 CELLS FOR THE TREATMENT OF CANCER | |
| IL249424A0 (en) | Car-expressing nk-92 cells as cell therapeutic agents | |
| EP2968549A4 (en) | CELL CULTURE METHOD | |
| DK3461491T3 (da) | Forbedret adoptiv celleterapi | |
| IL246262A0 (en) | Media for cell culture | |
| EP2968502A4 (en) | METHOD FOR CONTROLLING T-CELL PROLIFERATION | |
| DK3224351T3 (da) | Dyrkningsmedium til ekspandering af brystepitelstamceller | |
| PT2953634T (pt) | Métodos de expansão ou depleção das células t reguladoras | |
| GB2525104B (en) | Massively Parallel Single Cell Nucleic Acid Analysis | |
| EP3390695A4 (en) | ELECTROCHEMICAL HIGH PRESSURE CELL | |
| IL235443B (en) | Improved methods of cell culture for adoptive cell therapy | |
| HUE040233T2 (hu) | Szérummentes sejtkultúra-tápközeg | |
| HUE051105T2 (hu) | Sejt életképességének javítására szolgáló készítmények és azok alkalmazására szolgáló eljárások | |
| IL254639B (en) | Digital analysis of cancer cells moving in the bloodstream in blood samples | |
| FI20125997L (fi) | Kolmiulotteinen soluviljely | |
| IL270974A (en) | Methods of determining therapies based on single cell characterization of circulating tumor cells (ctcs) in metastatic disease | |
| IL290429A (en) | Improved methods of genetically modifying animal cells | |
| IL250830B (en) | Early lung cancer detection by dna methylation phenotyping of sputum-derived cells | |
| DK3766582T3 (da) | Cellekultur | |
| EP4012024C0 (en) | METHOD FOR IMPROVING CELL THERAPY | |
| EP3692914C0 (en) | BLOOD SAMPLE MANAGEMENT USING OPEN CELL FOAM | |
| LT3064575T (lt) | Pliuripotentinių kamieninių ląstelių, indikuotų iš mezenchiminių kamieninių ląstelių, diferenciacijos į hepatocitus būdas |